{"prompt": "['STABILITY 2', 'Version 1.4', 'PRO19020231', 'February 2, 2021', 'of North America and the International Arthroscopy Association. 2012;28(4):526-', '531.', '89.', 'Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed:', 'Hillsdale, NJ; 1988.', '90.', 'Skrondal AR-H, S. Protective estimation of mixed-effects logistic regression', 'when data are not missing at random. Biometrika. 2014;101(1):175-188.', '91.', 'Drummond M, Barbieri M, Cook J, et al. Transferability of economic evaluations', 'across jurisdictions: ISPOR Good Research Practices Task Force report. Jun.', '009;12(4):409-418.', '92.', 'Manca A, Rice N, Sculpher MJ, Briggs AH. Assessing generalisability by location', 'in trial-based cost-effectiveness analysis: the use of multilevel models. Jul.', '2005;14(5):471-485.', '93.', 'Manca A, Sculpher MJ, Goeree R. The analysis of multinational cost-', 'effectiveness data for reimbursement decisions: a critical appraisal of recent', 'methodological developments. The analysis of multinational cost-effectiveness', 'data for reimbursement decisions: a critical appraisal of recent methodological', 'developments. 2010;28(12):1079-1096.', '94.', \"Pinto EM, Willan AR, O'Brien BJ. Cost-effectiveness analysis for multinational\", 'clinical trials. Stat Med. 2005;24(13): 1965-1982.', '95.', 'Hoch JS, Briggs AH, Willan AR. Something old, something new, something', 'borrowed, something blue: a framework for the marriage of health econometrics', 'and cost-effectiveness analysis. Jul. 2002;11(5):415-430.', '96.', 'Hoch JS, Rockx MA, Krahn AD. Using the net benefit regression framework to', 'construct cost-effectiveness acceptability curves: an example using data from a', 'trial of external loop recorders versus Holter monitoring for ambulatory monitoring', 'of \"community acquired\" syncope. BMC Health Serv Res. 2006;6:68.', '97.', 'van Buuren S. Multiple imputation of discrete and continuous data by fully', 'conditional specification. Jun. 2007;16(3):219-242.', '98.', 'Taichman DB, Sahni P, Pinborg A, et al. Data Sharing Statements for Clinical', 'Trials: A Requirement of the International Committee of Medical Journal Editors.', '06. 2017;317(24):2491-2492', '115']['STABILITY 2', 'PRO19020231', 'Version 1.4', 'February 2, 2021', 'APPENDICES', '116']['STABILITY 2', 'Version 1.4', 'PRO19020231', 'February 2, 2021', 'APPENDIX A: STUDY TIMELINE', 'Aim 1: Determine if graft type (QT, BPTB or HT) with or without a LET affects the rate of ACL clinical failure at 2 years', 'after ACLR. ACL clinical failure will be defined by either graft rupture, symptomatic instability or persistent rotational laxity', '(asymmetrical positive pivot shift), at 2 years after ACLR.', 'Aim 2: Determine if graft type (QT, BPTB or HT) with or without a LET affects patient-reported symptoms, function and', 'quality of life, performance-basec measures of function and return-to-sports 2 years after ACLR.', 'Aim 3: Determine if graft type (QT, BPTB or HT) with or without a LET affects the rates of intervention-related donor site', 'morbidity, complications and adverse outcomes 2 years after ACLR.', 'Aim 4: Determine if the use of a particular graft type (QT, BPTB or HT) with or without LET is a more cost-effective', 'approach to ACLR.', 'Abbreviations: CCC = Clinical Coordinating Center; DCC = Data Coordinating Center; SS = Study Sites', 'Year 1', 'Year 2', 'Year 3', 'Year 4', 'Year 5', 'Phase 1', 'Phase 2', 'Major Tasks', 'Sites involved', '1', '2', '3', '4', '5', '6', '7-12', '13-24', '25-30', '31-36', '37-48', '49-57', '58-60', 'Study Start-up', 'X', 'X', 'X', 'CCC, DCC, SS', 'Subject Recruitment', 'X', 'X', 'X', 'CCC, DCC, SS', 'Clinical Monitoring &', 'CCC, DCC', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Quality Control', 'Subject Follow-up', 'X', 'X', 'X', 'X', 'X', 'X', 'CCC, SS', 'Study Governance', 'X', 'X', 'X', 'X', 'X', 'X', 'CCC, DCC, SS', 'Analyze &', 'CCC, DCC, SS', 'X', 'Disseminate Results', '117']\n\n###\n\n", "completion": "END"}